⌕
Enliven Therapeutics · ELVN · Nasdaq
Tenet 59 · Mixed
Compare
$47.62−2.42%At closeTenet 59 · Mixed
$47.62−1.18 (−2.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Enliven Therapeutics (ELVN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+59.4%) and Capex step-up ($158.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼16.5%
−103.7
FY21→FY25CAGR —
Free cash flow ($M)▲3.8%
−70.5
capex stepped upCAGR —
Diluted EPS▲3.2%
−1.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+59.4%

35.5mn → 56.7mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$158.0K

▲259% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−85.9R&D−33.8SG&A−119.7Op income16.0Tax & other−103.7Net income

Margin trend · direction beats level
108530%sector median net margin ~4%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7266, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
98,952.085,856.080,778.064,574.031,022.038,442.0▲6.3%+22.2%
Selling, general & admin
36,410.033,802.023,776.018,955.07,769.013,000.0▲42.2%+27.0%
Total operating expenses
135,362.0119,658.0104,554.083,529.038,791.051,442.0▲14.4%+23.5%
Operating incomefeeds ROC rank
−135,362.0−119,658.0−104,554.0−83,529.0−38,791.0−51,442.0▼14.4%—
Other income, net
21,880.015,964.014,889.011,945.01,129.058.0——
Pretax income
−113,482.0−103,694.0−89,665.0−71,584.0−37,662.0−51,384.0▼15.6%—
Income tax
—0.0232.00.0—0.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−113,482.0−103,694.0−89,024.0−71,584.0−37,662.0−51,384.0▼16.5%—
Per share
Diluted EPSbuyback-sensitive
−1.68−1.83−1.89−2.01−12.05−2.37▲3.2%—
Diluted shares (mn)
77.9856.6647.0735.553.1221.66▲20.4%+27.2%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.